JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB983

Anti-Insulin Receptor beta抗体[18-44]

Anti-Insulin Receptor beta antibody [18-44]

5

(2 Reviews)

|

(10 Publications)

Mouse Monoclonal Insulin Receptor beta antibody. Suitable for Flow Cyt and reacts with Human samples. Immunogen corresponding to Native Full Length Protein corresponding to Human INSR.

查看别名

CD220, Insulin receptor, IR

1 Images
Flow Cytometry - Anti-Insulin Receptor beta antibody [18-44] (AB983)
  • Flow Cyt

Unknown

Flow Cytometry - Anti-Insulin Receptor beta antibody [18-44] (AB983)

Overlay histogram showing HepG2 cells stained with ab983 (red line). The cells were fixed with 4% paraformaldehyde (10 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab983, 1μg/1x106 cells) for 30 min at 22°C. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H+L) (ab96879) at 1/500 dilution for 30 min at 22°C. Isotype control antibody (black line) was mouse IgG2b [PLPV219] (ab91366, 2μg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed. This antibody gave a positive signal in HepG2 cells fixed with 80% methanol (5 min)/permeabilized with 0.1% PBS-Tween for 20 min used under the same conditions.

This image was generated using the ascites version of the product.

关键信息

宿主种属

Mouse

克隆

Monoclonal

克隆号

18-44

亚型

IgG2b

不含载体蛋白

No

反应种属

Human

应用

Flow Cyt

applications

免疫原

Native Full Length Protein corresponding to Human Insulin receptor beta.

P06213

特异性

This antibody reacts specifically with the beta subunit of the insulin receptor.

反应性数据

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "FlowCyt-species-checked": "testedAndGuaranteed", "FlowCyt-species-dilution-info": "1 µg for 10^6 Cells", "FlowCyt-species-notes": "<p><a href='/products/primary-antibodies/mouse-igg2b-kappa-monoclonal-7e10g10-isotype-control-ab170192'>ab170192</a> - Mouse monoclonal IgG2b, is suitable for use as an isotype control with this antibody.</p>" } } }

产品详情

This product was changed from ascites to tissue culture supernatant on 19/12/2018. Please note that the dilutions may need to be adjusted accordingly. If you have any questions please do not hesitate to contact our scientific support team.

性能和储存信息

形式
Liquid
纯化工艺
Affinity purification Protein G
纯化说明
Purified from TCS
存储溶液
pH: 7.4
运输条件
Blue Ice
推荐的短期储存条件
+4°C
推荐的长期储存条件
-20°C
分装信息
Upon delivery aliquot
储存信息
Avoid freeze / thaw cycle

补充信息

This supplementary information is collated from multiple sources and compiled automatically.

Insulin Receptor beta (IR beta) also known as IRB is a subunit of the insulin receptor which is a transmembrane protein deeply involved in cellular signal transduction. This receptor has two main subunits: alpha and beta. The insulin receptor beta is responsible for the transduction of insulin's metabolic and mitogenic signals through its intrinsic tyrosine kinase activity. This subunit has a molecular mass of approximately 95 kDa and is predominantly expressed on the surface of insulin-responsive cells like liver muscle and adipose tissue cells where it mediates glucose uptake and metabolism. Its expression is usually determined through methods such as insulin western blot.
Biological function summary

The function of insulin receptor beta involves both glucose homeostasis and growth regulation as part of the tetrameric insulin receptor complex. Upon insulin binding to the receptor IR beta undergoes autophosphorylation leading to the recruitment and phosphorylation of various intracellular substrates. This interaction plays a critical role in mediating the effects of insulin such as promoting glucose uptake in cells and modulating lipid metabolism. This receptor subunit is also referred to in studies as insulin 44 or insulin 37 referring to different conceptual sizes or regulatory stages.

Pathways

The insulin signaling pathway represents the main route facilitated by insulin receptor beta. This pathway is essential for regulating glucose transport lipid metabolism and protein synthesis. Perturbations in this cascade are commonly associated with insulin resistance. The insulin receptor beta interacts with other proteins like insulin receptor substrates (IRS) during this pathway which subsequently activate key downstream pathways such as the PI3K-AKT pathway critical for cell survival and growth. This protein also plays a role in MAP kinase signaling through which it impacts gene expression related to cell growth.

Insulin receptor beta relates prominently to type 2 diabetes mellitus and metabolic syndrome. Mutations or dysfunctions in IR beta can lead to defective insulin signaling causing insulin resistance a major hallmark of these conditions. Additionally it is implicated in polycystic ovary syndrome (PCOS) where altered insulin signaling influences the endocrine and metabolic profiles. Proteins like insulin receptor substrates are often examined in these contexts as they directly interact with IR beta and modulate the downstream effects seen in these diseases.

产品实验方案

For this product, it's our understanding that no specific protocols are required. You can visit:

靶点信息

Receptor tyrosine kinase which mediates the pleiotropic actions of insulin. Binding of insulin leads to phosphorylation of several intracellular substrates, including, insulin receptor substrates (IRS1, 2, 3, 4), SHC, GAB1, CBL and other signaling intermediates. Each of these phosphorylated proteins serve as docking proteins for other signaling proteins that contain Src-homology-2 domains (SH2 domain) that specifically recognize different phosphotyrosine residues, including the p85 regulatory subunit of PI3K and SHP2. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways : the PI3K-AKT/PKB pathway, which is responsible for most of the metabolic actions of insulin, and the Ras-MAPK pathway, which regulates expression of some genes and cooperates with the PI3K pathway to control cell growth and differentiation. Binding of the SH2 domains of PI3K to phosphotyrosines on IRS1 leads to the activation of PI3K and the generation of phosphatidylinositol-(3, 4, 5)-triphosphate (PIP3), a lipid second messenger, which activates several PIP3-dependent serine/threonine kinases, such as PDPK1 and subsequently AKT/PKB. The net effect of this pathway is to produce a translocation of the glucose transporter SLC2A4/GLUT4 from cytoplasmic vesicles to the cell membrane to facilitate glucose transport. Moreover, upon insulin stimulation, activated AKT/PKB is responsible for : anti-apoptotic effect of insulin by inducing phosphorylation of BAD; regulates the expression of gluconeogenic and lipogenic enzymes by controlling the activity of the winged helix or forkhead (FOX) class of transcription factors. Another pathway regulated by PI3K-AKT/PKB activation is mTORC1 signaling pathway which regulates cell growth and metabolism and integrates signals from insulin. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 thereby activating mTORC1 pathway. The Ras/RAF/MAP2K/MAPK pathway is mainly involved in mediating cell growth, survival and cellular differentiation of insulin. Phosphorylated IRS1 recruits GRB2/SOS complex, which triggers the activation of the Ras/RAF/MAP2K/MAPK pathway. In addition to binding insulin, the insulin receptor can bind insulin-like growth factors (IGFI and IGFII). Isoform Short has a higher affinity for IGFII binding. When present in a hybrid receptor with IGF1R, binds IGF1. PubMed : 12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed : 16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin. In adipocytes, inhibits lipolysis (By similarity).
See full target information Insulin receptor beta

文献 (10)

Recent publications for all applications. Explore the full list and refine your search

Cells 14: PubMed40643462

2025

Insulin Modulates NK Cell Activity in Liver Fibrosis MASH Patients via the STING Pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Johnny Amer,Ahmad Salhab,Amiram Ariel,Rifaat Safadi

American journal of physiology. Heart and circulatory physiology 323:H688-H701 PubMed36018759

2022

ADAM17 cleaves the insulin receptor ectodomain on endothelial cells and causes vascular insulin resistance.

Applications

Unspecified application

Species

Unspecified reactive species

Thaysa Ghiarone,Jorge A Castorena-Gonzalez,Christopher A Foote,Francisco I Ramirez-Perez,Larissa Ferreira-Santos,Francisco J Cabral-Amador,Roger de la Torre,Rama R Ganga,Andrew A Wheeler,Camila Manrique-Acevedo,Jaume Padilla,Luis A Martinez-Lemus

Journal of biochemical and molecular toxicology 34:e22504 PubMed32227688

2020

Triflumuron induces cytotoxic effects on hepatic and renal human cell lines.

Applications

Unspecified application

Species

Unspecified reactive species

Rim Timoumi,Ines Amara,Intidhar Ben Salem,Salwa Abid-Essefi

Nature communications 10:1981 PubMed31040273

2019

Liver-target nanotechnology facilitates berberine to ameliorate cardio-metabolic diseases.

Applications

Unspecified application

Species

Unspecified reactive species

Hui-Hui Guo,Chen-Lin Feng,Wen-Xuan Zhang,Zhi-Gang Luo,Hong-Juan Zhang,Ting-Ting Zhang,Chen Ma,Yun Zhan,Rui Li,Song Wu,Zeper Abliz,Cong Li,Xiao-Lin Li,Xiao-Lei Ma,Lu-Lu Wang,Wen-Sheng Zheng,Yan-Xing Han,Jian-Dong Jiang

PloS one 14:e0214254 PubMed30901379

2019

Aberrant insulin receptor expression is associated with insulin resistance and skeletal muscle atrophy in myotonic dystrophies.

Applications

Unspecified application

Species

Unspecified reactive species

Laura Valentina Renna,Francesca Bosè,Elisa Brigonzi,Barbara Fossati,Giovanni Meola,Rosanna Cardani

The Journal of endocrinology 218:B1-8 PubMed23759446

2013

Evidence for an interaction between proinsulin C-peptide and GPR146.

Applications

ICC/IF

Species

Unspecified reactive species

Gina L C Yosten,Grant R Kolar,Lauren J Redlinger,Willis K Samson

Molecular genetics and metabolism 94:356-62 PubMed18411068

2008

Two novel mutations in the insulin binding subunit of the insulin receptor gene without insulin binding impairment in a patient with Rabson-Mendenhall syndrome.

Applications

ICC/IF

Species

Human

Christian T Thiel,Birgit Knebel,Ina Knerr,Heinrich Sticht,D Müller-Wieland,Martin Zenker,Andre Reis,Helmuth-Günther Dörr,Anita Rauch

The Biochemical journal 268:615-20 PubMed1694662

1990

Anti-(insulin receptor) monoclonal antibody-stimulated tyrosine phosphorylation in cells transfected with human insulin receptor cDNA.

Applications

Unspecified application

Species

Unspecified reactive species

N P Brindle,J M Tavare,M Dickens,J Whittaker,K Siddle

The Journal of biological chemistry 265:9970-7 PubMed1693619

1990

Identification of epitopes on the human insulin receptor reacting with rabbit polyclonal antisera and mouse monoclonal antibodies.

Applications

Unspecified application

Species

Unspecified reactive species

S A Prigent,K K Stanley,K Siddle

The Biochemical journal 235:199-208 PubMed2427071

1986

Monoclonal antibodies reacting with multiple epitopes on the human insulin receptor.

Applications

Unspecified application

Species

Unspecified reactive species

M A Soos,K Siddle,M D Baron,J M Heward,J P Luzio,J Bellatin,E S Lennox
View all publications

Abcam Product Promise

我们致力于为您的研究提供高质量的试剂,为您科研的每一步提供支持。若我们的产品未能达到预期性能,我们向您提供 Abcam Product Promise 保障。
详情请参阅我们的条款与条件。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com